Literature DB >> 19912203

Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.

Florian R Schroeck1, Michael W Kattan, Judd W Moul, William J Aronson, Joseph C Presti, Martha K Terris, Christopher J Kane, Christopher L Amling, Leon Sun, Stephen J Freedland.   

Abstract

OBJECTIVE: To re-calibrate the previously published Duke Prostate Center (DPC) nomogram for the prediction of biochemical recurrence (BCR) after radical prostatectomy (RP) to not only predict overall BCR but also the clinically more relevant endpoint of an aggressive recurrence (i.e. a BCR with a postoperative PSA doubling time (PSADT) of <9 months). PATIENTS AND METHODS: Using the established point-scale system based upon the previously published DPC nomogram, we re-calibrated this point system to predict not just BCR, but also aggressive BCR within 2599 men treated with RP from the DPC database. PSADT was computed on all patients meeting the recurrence definition who had a minimum of two PSA values, separated by at least 3 months, and < or =2 years after recurrence. External validation was performed using data from 1695 men treated with RP within the Shared Equal Access Regional Cancer Hospital (SEARCH) database by calculating the concordance index c and by plotting calibration curves.
RESULTS: The median follow-up for patients with no BCR was 56 and 47 months for DPC and SEARCH, respectively. In the DPC modelling cohort and the SEARCH validation cohort, 645 (25%) and 557 (33%) men had BCR, while 83 (3.2%) and 71 (4.2%) patients had an aggressive recurrence. In external validation, predictive accuracy for an aggressive BCR was high (c = 0.83) and the nomogram showed good calibration.
CONCLUSIONS: We re-calibrated an existing nomogram to not only predict overall BCR after RP but also aggressive recurrence after RP. Our new tool can provide valuable information for patient counselling and patient selection for adjuvant therapy trials.

Entities:  

Mesh:

Year:  2009        PMID: 19912203      PMCID: PMC7252932          DOI: 10.1111/j.1464-410X.2009.09060.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

1.  Predicting outcomes in prostate cancer: how many more nomograms do we need?

Authors:  Robert W Ross; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

2.  PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Authors:  S G Roberts; M L Blute; E J Bergstralh; J M Slezak; H Zincke
Journal:  Mayo Clin Proc       Date:  2001-06       Impact factor: 7.616

3.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

4.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Christopher J DiBlasio; Alwyn Reuther; Eric A Klein; Michael W Kattan
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

5.  Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

Review 6.  An updated catalog of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Pierre I Karakiewicz; Claus G Roehrborn; Michael W Kattan
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

7.  Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.

Authors:  F R Schroeck; L Sun; S J Freedland; J Jayachandran; C N Robertson; J W Moul
Journal:  Prostate Cancer Prostatic Dis       Date:  2008-04-22       Impact factor: 5.554

8.  Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Shahrokh F Shariat; Michael J Zelefsky; Michael W Kattan; E Brian Butler; Bin S Teh; Eric A Klein; Patrick A Kupelian; Claus G Roehrborn; David A Pistenmaa; Heather D Pacholke; Stanley L Liauw; Matthew S Katz; Steven A Leibel; Peter T Scardino; Kevin M Slawin
Journal:  JAMA       Date:  2004-03-17       Impact factor: 56.272

9.  Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?

Authors:  Florian R Schroeck; William J Aronson; Joseph C Presti; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  BJU Int       Date:  2008-11-18       Impact factor: 5.588

10.  Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.

Authors:  S J Freedland; M Jalkut; F Dorey; M E Sutter; W J Aronson
Journal:  Urology       Date:  2000-07       Impact factor: 2.649

View more
  3 in total

1.  Radiation therapy in prostate cancer: a risk-adapted strategy.

Authors:  A J Hayden; C Catton; T Pickles
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

2.  Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group.

Authors:  Anna E Teeter; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2013-07       Impact factor: 2.649

3.  Prognostic factors for failure after prostatectomy.

Authors:  Gregory P Swanson; Joseph W Basler
Journal:  J Cancer       Date:  2010-12-07       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.